Fluoguide AS EBITDA per Share
EBITDA per Share of Fluoguide AS (FLUO.ST) as of Oct 25, 2026.
Get this data via API
Financial Data API
EBITDA per Share
-DKK
Last updated:
EBITDA per Share of Fluoguide AS is 2026 - DKK. EBITDA per Share of Fluoguide AS was 2025 - DKK. It decreases by % lower compared to the previous year.
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Fluoguide AS Stock analysis
What does Fluoguide AS do? Fluoguide AS is a clinical stage biotechnology company based in Copenhagen, Denmark, operating in the Health Care sector. The company develops surgical solutions using its uPAR technology platform to illuminate cancer cells during surgery, aiming to improve surgical precision and outcomes. Its main product, FG001, targets various cancers including lung, head & neck, meningioma, and low-grade glioma, with the goal of reducing patient pain, enhancing recovery, and lowering healthcare costs. Listed on 7 May 2019, Fluoguide employs eight people. Fluoguide AS is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Fluoguide AS stock
On Eulerpool you can find the complete historical development of EBITDA per Share Fluoguide AS since 2006 – with annual values, charts, and detailed analysis.
EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Income Statement — Fluoguide AS
All Key Metrics — Fluoguide AS
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth